Core Viewpoint - Algeria has made significant progress in the pharmaceutical export sector, marking a pivotal step with the export of natural rubber by IMGSA Group to China, which is known for its stringent quality and international compliance standards [1] Group 1: Export Developments - The export of natural rubber to China represents an important milestone for Algerian products entering the Chinese market [1] - A representative from the Chinese partner indicated that this export is a true starting point for Algeria's exports to China, expressing hopes for deeper cooperation and an expansion of product varieties in the coming years [1] Group 2: Market Demand - The Chinese partner has expressed a monthly demand for liquid calcium carbonate, with an estimated annual total demand of 500 tons [1] - These new prospects indicate that the Algerian pharmaceutical industry is actively developing and is capable of meeting foreign market requirements [1] Group 3: Strategic Goals - Algeria aims to become a reliable participant in the production and export of pharmaceutical products both regionally and on a broader scale [1]

Core Viewpoint - Recently, Sinovac Biotech (688136.SH) has received approval from Bolivia's National Medicines and Health Technologies Authority (AGEMED) for its biosimilar product, Bevacizumab, marking the fifth country where this product has been approved following its collaboration with Easton Pharmaceutical [1] Group 1: Product Approval and Market Expansion - Bevacizumab is a commonly used drug in oncology, applicable for various cancers including metastatic colorectal cancer, advanced/metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, tubal cancer, primary peritoneal cancer, and cervical cancer [1] - The approval in Bolivia is part of a broader trend, as Sinovac's pharmaceutical exports to emerging markets such as ASEAN, Latin America, and Africa are steadily increasing, with Latin America seeing an 11.4% growth [1] - Sinovac has established a subsidiary in Latin America and formed a localized operational team to enhance market penetration and improve drug accessibility in the region [1] Group 2: International Registration Progress - Since the beginning of this year, multiple Sinovac products have received market approval in various countries, with Bevacizumab biosimilar already registered in five countries including Pakistan and Indonesia [1] - There are over twenty additional countries where registration efforts for the product are rapidly advancing [1]